Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014;10(10):2795-8.
doi: 10.4161/21645515.2014.970494.

Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age

Sven A Silfverdal  1 , Deepak Assudani, Sherine Kuriyakose, Olivier Van Der Meeren
Affiliations

Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age

Sven A Silfverdal et al. Hum Vaccin Immunother. 2014.

Abstract

The combined diphtheria-tetanus-acellular pertussis-hepatitis B-poliomyelitis/Haemophilus influenza vaccine (DTPa-HBV-IPV/Hib: Infanrix™ hexa, GlaxoSmithKline Vaccines) is used for primary vaccination of infants in a range of schedules world-wide. Antibody persistence after 4 DTPa-HBV-IPV/Hib doses in the first 2 y of life has been documented, but long-term persistence data following the 3, 5, 11-12 months (3-5-11) infant vaccination schedule, employed for example in Nordic countries, are limited. We assessed antibody persistence in 57 5-year-old children who had received either DTPa-HBV-IPV/Hib or DTPa-IPV/Hib (Infanrix™-IPV/Hib, GlaxoSmithKline Vaccines) in the 3-5-11 schedule. Among DTPa-HBV-IPV/Hib recipients, 7/12 retained seroprotective antibody concentrations for diphtheria, 10/12 for tetanus, 5/12 for hepatitis and 10/12 for Hib. Detectable antibodies were observed for 0/12 children for pertussis toxin (PT), 12/12 for filamentous haemagglutinin (FHA) and 8/12 for pertactin (PRN). Among DTPa-IPV/Hib recipients, 28/45 retained seroprotective anti-diphtheria concentrations, 34/44 for tetanus and 40/45 for Hib. Detectable antibodies were observed for 9/45 children for PT, 41/45 for FHA and 34/45 for PRN. Antibody persistence in DTPa-HBV-IPV/Hib and DTPa-IPV/Hib-vaccinees appeared similar in 5 y olds to that previously observed in children of a similar age who had received 4 prior doses of DTPa-HBV-IPV/Hib (or DTPa-IPV/Hib). As in subjects primed with 4 prior doses, we observed that antibodies markedly declined by 5 y of age, calling for the administration of a pre-school booster dose in order to ensure continued protection against pertussis.

Keywords: CI, confidence interval; DTPa-HBV-IPV/Hib, - diphtheria-tetanus-acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine; DTPa-IPV/Hib, diphtheria-tetanus-acellular pertussis-inactivated poliovirus and Haemophilus influenzae type b vaccine; FHA, filamentous haemagglutinin; GMC, geometric mean antibody concentration; HBs, anti-hepatitis B surface antigen; Hib, Haemophilus influenzae type b; NA, not applicable; PRN, pertactin; PRP, polyribosylribitol phosphate; PT, pertussis toxin; antibody persistence; booster; vaccination schedule; vaccine; μg/ml, micrograms per milliliter.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Subject disposition.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt H-J, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006; 25:507-12; PMID:16732148; http://dx.doi.org/10.1097/01.inf.0000222413.47344.23 - DOI - PubMed
    1. Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007; 26:496-500; PMID:17529866; http://dx.doi.org/10.1097/INF.0b013e31805d7f17 - DOI - PubMed
    1. Carlsson RM, Claesson BA, Selstam U, Fagerlund E, Granström M, Blondeau C, Hoffenbach A. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998; 17:1026-33; PMID:9849987; http://dx.doi.org/10.1097/00006454-199811000-00013 - DOI - PubMed
    1. Taranger J, Trollfors B, Knutsson N, Sundh V, Lagergård T, Ostergaard E. Vaccination of infants with a four-dose and a three-dose vaccination schedule. Vaccine 1999; 18:884-91; PMID:10580202; http://dx.doi.org/10.1016/S0264-410X(99)00341-2 - DOI - PubMed
    1. Heininger U, Sänger R, Jacquet J-M, Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007; 25:1055-63; PMID:17049692; http://dx.doi.org/10.1016/j.vaccine.2006.09.060 - DOI - PubMed

Publication types

MeSH terms

Substances